### Highlights of This Issue 2919

#### SPECIAL FEATURES

**New Strategies for Treatment of KRAS Mutant Metastatic Colorectal Cancer**
Hans Prenen, Sabine Tejpar, and Eric Van Cutsem

**CXCL12 (SDF-1)/CXCR4 Pathway in Cancer**
Beverly A. Teicher and Simon P. Fricker

**Control of Tumorigenesis and Chemoresistance by the DEK Oncogene**
Erica Riveiro-Falkenbach and María S. Soengas

**The Proapoptotic Molecule BLID Interacts with Bcl-X<sub>L</sub> and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival**
Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca Riggins, Anne-Michelle Noone, Bassem R. Haddad, Françoise Seiller-Moiseiwitsch, Bhaskar V.S. Kallakury, Bruce G. Haffty, Robert Clarke, and Usha N. Kasid

**The Proapoptotic Molecule BLID Interacts with Bcl-X<sub>L</sub> and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival**
Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca Riggins, Anne-Michelle Noone, Bassem R. Haddad, Françoise Seiller-Moiseiwitsch, Bhaskar V.S. Kallakury, Bruce G. Haffty, Robert Clarke, and Usha N. Kasid

### Molecular Pathways

**CXCL12 (SDF-1)/CXCR4 Pathway in Cancer**
Beverly A. Teicher and Simon P. Fricker

**Control of Tumorigenesis and Chemoresistance by the DEK Oncogene**
Erica Riveiro-Falkenbach and María S. Soengas

### HUMAN CANCER BIOLOGY

**The Proapoptotic Molecule BLID Interacts with Bcl-X<sub>L</sub> and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival**
Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca Riggins, Anne-Michelle Noone, Bassem R. Haddad, Françoise Seiller-Moiseiwitsch, Bhaskar V.S. Kallakury, Bruce G. Haffty, Robert Clarke, and Usha N. Kasid

**The Proapoptotic Molecule BLID Interacts with Bcl-X<sub>L</sub> and Its Downregulation in Breast Cancer Correlates with Poor Disease-Free and Overall Survival**
Constantinos G. Broustas, Jeffrey S. Ross, Qifeng Yang, Christine E. Sheehan, Rebecca Riggins, Anne-Michelle Noone, Bassem R. Haddad, Françoise Seiller-Moiseiwitsch, Bhaskar V.S. Kallakury, Bruce G. Haffty, Robert Clarke, and Usha N. Kasid

**The Tumor Suppressor UCHL1 Forms a Complex with p53/MDM2/ARF to Promote p53 Signaling and Is Frequently Silenced in Nasopharyngeal Carcinoma**
Lili Li, Qian Tao, Hongchuan Jin, Andrew van Hasselt, Fan Fong Poon, Xian Wang, Mu-Sheng Zeng, Wei-Hua Jia, Yi-Xin Zeng, Anthony T.C. Chan, and Ya Cao

### CANCER THERAPY: PRECLINICAL

**The Transcriptional Coregulator RIP140 Represses E2F1 Activity and Discriminates Breast Cancer Subtypes**
Aurélie Docquier, Pierre-Olivier Harmand, Samuel Fritsch, Maia Chantrion, Jean-Marie Darbon, and Vincent Cavailles

**Chromosomal and MicroRNA Expression Patterns Reveal Biologically Distinct Subgroups of 11q- Neuroblastoma**

**Telomere Maintenance and DNA Damage Responses during Lung Carcinogenesis**
Sylvie Lantuejoul, Christophe Raynaud, Dimitri Salameire, Sylvie Gazzetti, Denis Moro-Sibilot, Jean-Charles Soria, Christian Brambilla, and Elizabeth Brambilla

**Assessment of the In vivo Antitumor Effects of ENMD-2076, a Novel Multitargeted Kinase Inhibitor, against Primary and Cell Line–Derived Human Colorectal Cancer Xenograft Models**
John J. Tentler, Erica L. Bradshaw-Pierce, Natalie J. Serkova, Kendra M. Hasebroock, Todd M. Piits, Jennifer R. Diamond, Graham C. Fletcher, Mark R. Bray, and S. Gail Eckhardt

**Insulin-like Growth Factor 2 Expression Modulates Taxol Resistance and Is a Candidate Biomarker for Reduced Disease-Free Survival in Ovarian Cancer**
Phase 1 Study of AMG 386, a Selective Angiopoietin 1/2–Neutralizing Peptibody, in Combination with Chemotherapy in Adults with Advanced Solid Tumors

A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong, George J. Netto, Michelle A. Rudek, Susan Halabi, David P. Wood, Patricia A. Cree, Kelly Mundy, S. Lindsay Davis, Ting Wang, Roula Albadine, Luciana Schultz, Alan W. Partin, Antonio Jimeno, Helen Fedor, Phillip G. Febbo, Daniel J. George, Robin Gurganus, Angelo M. De Marzo, and Michael A. Carducci

Clinical and Correlative Results of SWOG S0354: A Phase II Trial of CNTO328 (Siltuximab), a Monoclonal Antibody against Interleukin-6, in Chemotherapy-Pretreated Patients with Castration-Resistant Prostate Cancer
Tanya B. Dorff, Bryan Goldman, Jacek K. Pinski, Philip C. Mack, Primo N. Lara, Jr., Peter J. Van Veldhuizen, Jr., David I. Quinn, Nicholas J. Vogelzang, Ian M. Thompson, Jr., and Maha H.A. Hussain

Oncolytic Adenovirus ICOVIR-7 in Patients with Advanced and Refractory Solid Tumors
Petri Nokisalmi, Sari Pesonen, Sophie Escutenaire, Merja Särkioja, Mari Raki, Vincenzo Cerullo, Leena Laasonen, Ramon Alemany, Juan Rojas, Manel Cascallo, Kilian Guse, Maria Rajeczi, Lotta Kangasniemi, Elna Haavisto, Aila Karioja-Kallio, Paivi Hannukosela, Minna Oksanen, Anna Kanerva, Timo Joensuu, Laura Abtaiinen, and Akseli Hemminki

A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
ABOUT THE COVER

BLID expression was found to be lost or decreased in several invasive ductal breast carcinomas (IDC). The cover image shows an example of BLID-negative IDC as determined by immunohistochemistry using a breast tumor tissue microarray. Lack of BLID was associated with poor prognostic factors and survival. For details, see the article by Broustas and colleagues on page 2939 of this issue.
Clinical Cancer Research

16 (11)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/16/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.